Incidence of Metastasis in the Central Nervous System in Advanced Breast Cancer Treated With CDK 4/6 Inhibitors: A Multicenter, Retrospective Study
Abstract Central nervous system (CNS) metastasis remains a major cause of mortality in advanced breast cancer (ABC). While cyclin‐dependent kinase 4/6 inhibitors (CDKIs) combined with endocrine therapy (ET) delay resistance in hormone receptor (HR)‐positive and human epidermal growth factor receptor...
Saved in:
| Main Authors: | Yan‐Ling Wen, Xi‐Wen Bi, Xue‐Wen Zhang, Si‐Fen Wang, Chang Jiang, Li Wang, Yong‐Yi Zhong, Yuan‐Yuan Huang, Jian‐Li Zhao, Qian‐Jun Chen, Cong Xue, Zhong‐Yu Yuan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.70221 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial
by: Jiayu Wang, et al.
Published: (2025-06-01) -
Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis
by: Yanrong Kang, et al.
Published: (2025-05-01) -
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01) -
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer
by: Sarah Alexandrou, et al.
Published: (2025-08-01) -
First-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report
by: Eko Adhi Pangarsa, et al.
Published: (2024-12-01)